Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva plataforma para aumentar la rentabilidad de líneas celulares que secretan proteínas recombinantes, anticuerpos monoclonales o biosimilares

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOBE20171024001
Publicado:
10/01/2018
Caducidad:
10/01/2019
Resumen:
Una empresa belga ofrece una tecnología única para aumentar la productividad y estabilidad de líneas celulares de forma permanente, permitiendo la fabricación rentable y eficiente (GMP - Buenas Prácticas de Manufactura) de proteínas recombinantes, nuevas entidades biológicas difíciles de expresar o medicamentos biosimilares. La tecnología es universal en sus principios pero debe adaptarse a la línea celular o componentes biológicos aportados a la empresa. El protocolo a medida se revisa conforme a las necesidades del cliente en lo que concierne a la estabilidad de la línea celular, productividad, calidad y caracterización de proteínas. La empresa busca compañías biotecnológicas, farmacéuticas y de diagnóstico con el fin de establecer acuerdos comerciales con asistencia técnica.

Details

Tittle:
Innovative plateform to increase the profitability of cell lines secreting recombinant protein, monoclonal andibodies, or biosimilars
Summary:
A Belgian company offers a unique technology that increases in a permanent way cell line productivity and stability, allowing cost-effective and efficient GMP (Good Manufacturing Practices) manufacturing of recombinant protein, difficult-to-express new biological entities and biosimilars drugs.
The company is looking for commercial agreement with technical assistance with biotech pharma and diagnostic companies .
Description:
Cell lines are used in bioprocess for the production of biomolecules. Most of the time, cell lines should be more productive as it is.

The Belgian company has so developed a technology as a service solution that consists in physical stimulation treatments that improve cell line metabolism for biologics manufacturing in cell line such as Chinese Hamster Ovary (CHO cells), Human Embryonic Kidney (HEK293 cells), hybridomas, yeast, ...in order to increase cell productivity by a factor 3 to 10.
After technology application on its cell lines, the partner recovers super-producing cells. It gives a chance to cultivate cells in the same conditions as before and to produce more biologics. Risks that are linked to a stop of secretion are now banished.
The technology comes either as a unique solution or in synergy with cell culture media optimization, searching for cell culture parameters, and the use of gene-altering elements.
The technology is universal in its principles, however it must be adapted regarding the cell line and/or the biologics that will be provided to the company. This custom-made protocol will be reviewed in accordance to the customer needs in term of cel line stability, productivity, quality and protein characterization. Each project so require technical assistance in order to identify the best way for cell line optimization.

Part of company´s know-how consists into the stimulation treatments that trigger cell metabolism activation. This permanent effect leads to definitive improved cell metabolism and oxidative parameters along passages, required for achieving high and sustainable expression of the recombinant protein of interest at the largest scale.

Stimulations are safe for the cells and make no use of irradiation (UV, gamma, X-ray), neither viruses, antimetabolite treatment (e.g. methotrexate) nor recombination technologies to change the DNA structure of the genome or the insert.

Monoclonality demonstration is included into the process for the selection of the best "High Titer" clones.

The Belgian company is interested in applying the technology to new kinds of cell line as Proof of Concept, via commercial agreement with technical assistance.
Advantages and Innovations:
Stimulations are safe for the cells and make no use of irradiation (UV, gamma, X-ray), neither viruses, antimetabolite treatment (e.g. methotrexate) nor recombination technologies to change the DNA structure of the genome or the insert.
This technology allows to drastically decrease biomanufacturing cost of goods.

It also helps the Good Manufacturing Practices ( GMP) or non-GMP manufacturing of difficult-to-express proteins, new biological entities and Biosimilars.
Stage of Development:
Already on the market
IPs:
Secret Know-how

Partner sought

Type and Role of Partner Sought:
The Belgian company is looking for commercial partners that want to improve the profitability of their cell lines. The Belgian company currently works on all types of CHO cells, HEK cells, hybridomas,...

The Belgian company is looking for for Proof of Concept with partners to extend its technologies to other king of cells as yeast, VERO cells, insect cells...

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002001 Bioquímica / biofísica
06002004 Ingeniería de proteínas